Apyx Medical Corporation (APYX)

Compare

0.8800

-0.0200

(-2.22%)

At close: 4:00:02 PM EDT

0.8349

-0.05

(-5.12%)

After hours: 7:16:54 PM EDT

Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. The NewBeauty Awards franchise is a leading and trusted program in the beauty space. The award winners represent effective solutions to consumers' biggest beauty inter

PR Newswire 16 days ago

APYX
-2.22%
Apyx Medical Full Year 2024 Earnings: Beats Expectations

Apyx Medical ( NASDAQ:APYX ) Full Year 2024 Results Key Financial Results Revenue: US$48.1m (down 8.1% from FY 2023...

Simply Wall St. 27 days ago

APYX
-2.22%
Apyx Medical Corp (APYX) Q4 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

Apyx Medical Corp (APYX) reports a mixed quarter with revenue declines but showcases promising growth in advanced energy and strategic marketing efforts.

GuruFocus.com 27 days ago

APYX
-2.22%
Q4 2024 Apyx Medical Corp Earnings Call

Q4 2024 Apyx Medical Corp Earnings Call

Thomson Reuters StreetEvents 27 days ago

APYX
-2.22%
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

Apyx (APYX) delivered earnings and revenue surprises of 7.69% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 28 days ago

APYX
-2.22%
Apyx: Q4 Earnings Snapshot

CLEARWATER, Fla. AP) — Apyx Medical Corporation (APYX) on Thursday reported a loss of $4.6 million in its fourth quarter. On a per-share basis, the Clearwater, Florida-based company said it had a loss of 12 cents.

Associated Press Finance 28 days ago

APYX
-2.22%
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last yearSubmitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a planned launch in the back half of 2025, pending clearanceManagement to host a conference call today at 8:30 a.m. ET CLEARWATER, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:AP

GlobeNewswire 28 days ago

APYX
-2.22%
Apyx Medical Insiders Placed Bullish Bets Worth US$2.19m

Multiple insiders secured a larger position in Apyx Medical Corporation ( NASDAQ:APYX ) shares over the last 12 months...

Simply Wall St. last month

APYX
-2.22%
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of

GlobeNewswire last month

APYX
-2.22%
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

Advanced Energy revenue increase by more than 25% quarter-over-quarter in Q4 2024CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary: Total revenue expected to be in a range of appro

GlobeNewswire 2 months ago

APYX
-2.22%
Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™

Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suiteCLEARWATER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System.

GlobeNewswire 3 months ago

APYX
-2.22%
Why Is Apyx Medical Corporation (APYX) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where Apyx Medical Corporation (NASDAQ:APYX) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty, consumer preferences in the beauty industry are […]

Insider Monkey 3 months ago

APYX
-2.22%
Calculating The Intrinsic Value Of Apyx Medical Corporation (NASDAQ:APYX)

Key Insights The projected fair value for Apyx Medical is US$1.56 based on 2 Stage Free Cash Flow to Equity With...

Simply Wall St. 3 months ago

APYX
-2.22%
Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

CLEARWATER, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, in New York, NY. Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief

GlobeNewswire 4 months ago

APYX
-2.22%
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference

CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton NY Times Square Hotel, New York,

GlobeNewswire 4 months ago

APYX
-2.22%
Apyx Medical Third Quarter 2024 Earnings: EPS Beats Expectations

Apyx Medical ( NASDAQ:APYX ) Third Quarter 2024 Results Key Financial Results Revenue: US$11.5m (down 4.1% from 3Q...

Simply Wall St. 4 months ago

APYX
-2.22%
Apyx Medical Corp (APYX) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...

Despite a revenue dip, Apyx Medical Corp (APYX) focuses on growth through new product development and strategic investments.

GuruFocus.com 4 months ago

APYX
-2.22%
Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates

Apyx (APYX) delivered earnings and revenue surprises of 6.67% and 1.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

APYX
-2.22%
BRBR
Apyx: Q3 Earnings Snapshot

CLEARWATER, Fla. AP) — Apyx Medical Corporation (APYX) on Friday reported a loss of $4.7 million in its third quarter. On a per-share basis, the Clearwater, Florida-based company said it had a loss of 14 cents.

Associated Press Finance 4 months ago

APYX
-2.22%
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company’s common stock at a purchase price of $1.18 per share and pre-funded wa

GlobeNewswire 4 months ago

APYX
-2.22%

Performance Overview

Return	APYX	S&P 500 (^GSPC)
YTD	-44.30%	-10.43%
1-Year	-38.03%	+2.08%
3-Year	-84.70%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Apyx Medical Corporation (APYX)

Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

Apyx Medical Full Year 2024 Earnings: Beats Expectations

Apyx Medical Corp (APYX) Q4 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

Q4 2024 Apyx Medical Corp Earnings Call

Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

Apyx: Q4 Earnings Snapshot

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Apyx Medical Insiders Placed Bullish Bets Worth US$2.19m

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™

Why Is Apyx Medical Corporation (APYX) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?

Calculating The Intrinsic Value Of Apyx Medical Corporation (NASDAQ:APYX)

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference

Apyx Medical Third Quarter 2024 Earnings: EPS Beats Expectations

Apyx Medical Corp (APYX) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...

Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates

Apyx: Q3 Earnings Snapshot

Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

Performance Overview